-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sullivan insight
Recently, Alexion Pharmaceuticals (hereinafter referred to as "Alexion Pharmaceuticals"), a subsidiary of AstraZeneca's rare disease business, announced the acquisition of LogicBio Therapeutics
, a clinical-stage genetic company, for US$68 million (approximately RMB484 million).
In recent years, with policy support and market demand, many pharmaceutical companies, including Novartis and Takeda, are accelerating the layout of
rare diseases.
Why do large companies choose to deploy rare diseases in the form of mergers and acquisitions? In recent years, the research and development of rare disease drugs has become a hot spot for pharmaceutical companies, and the continuous influx of capital will bring to the entire industrial chain? Li Qian, senior consulting director of medical industry in Greater China at Frost & Sullivan ("Sullivan"), was interviewed by China Times to discuss the reasons and impacts
of large enterprises in the field of rare diseases.
China Times
China Times Multinational pharmaceutical giants are increasing their layout
in the field of rare diseases.
On October 3, Eastern time, Alexion Pharmaceuticals (hereinafter referred to as "Alexion Pharmaceuticals"), a subsidiary of AstraZeneca's rare disease business, announced the acquisition of LogicBio Therapeutics
, a clinical-stage genetic company, for $68 million (about 484 million yuan).
。 On the same day, Pfizer announced the acquisition of Biohaven for $11.
6 billion, and just two days later, Pfizer again announced the acquisition of GBT for $5.
4 billion, which was interpreted by the outside world as Pfizer began to look for new assets in the field of biopharmaceuticals to expand its pipeline and seize the field of
rare hematology.
In fact, Merck, Novartis and GlaxoSmithKline have invested heavily in rare disease acquisitions in the past year, while domestic pharmaceutical companies such as CANbridge, Boyaagen, Contini Pharmaceutical, Shanghai Zhongqiang Pharmaceutical, Sufang Pharmaceutical, and Deyi Sunshine are also actively deploying rare disease R&D
pipelines.
Li Qian
Li QianSenior Consulting Director, Healthcare Industry, Sullivan, Greater China
Senior Consulting Director, Healthcare Industry, Sullivan, Greater China "In recent years, rare diseases have become a hot investment area, and mergers and acquisitions of tens of billions of dollars are common
.
" Li Qian, senior consulting director of Sullivan Medical Industry, said in an interview with the China Times that pharmaceutical companies will face the crisis of product patent expiration and need to expand their product pipelines to achieve the purpose of sustainable growth, and mergers and acquisitions are one of the solutions
.
The continuous influx of capital will promote the development of the rare disease industry, and more patients with rare diseases will benefit from it
.
.
" Li Qian, senior consulting director of Sullivan Medical Industry, said in an interview with the China Times that pharmaceutical companies will face the crisis of product patent expiration and need to expand their product pipelines to achieve the purpose of sustainable growth, and mergers and acquisitions are one of the solutions
.
The continuous influx of capital will promote the development of the rare disease industry, and more patients with rare diseases will benefit from it
.
Add code layout
Add code layout Recently, AstraZeneca and its subsidiary Alex Pharma announced the acquisition of LogicBio Therapeu
.
It is reported that with this acquisition, LogicBio will bring unique technology, experienced rare disease team, and preclinical development expertise to support the development
of Alex Brother Pharma in genomic drugs.
According to public information, LogicBio was founded in 2014 as a clinical-stage genomic drug company based in Lexington, Massachusetts, treating a variety of genetic diseases, including rare diseases, and currently focusing on developing novel gene therapies
for pediatric patients with rare diseases.
LogicBio has developed technology platforms for delivering and inserting genes to address genetic diseases, as well as platforms
for improving the viral vector manufacturing process.
These platforms, combined with LogicBio's experienced team and advances in Alex and AstraZeneca, will drive future scientific possibilities and next-generation drugs
for the treatment of rare genetic diseases.
Mark Dunoyer, CEO of Alex Brother Pharmaceuticals, said: "The proposed acquisition of LogicBio is a significant development
for our growing genomic medical research.
LogicBio's people, experience, and platform provide new scientific capabilities
by adding best-in-class technology and expertise to our genomic medicine strategy.
Scientific collaboration between Alex and AstraZeneca has been an important area of focus since last year's acquisition, and the addition of LogicBio will expand this foundational work
.
”
Coincidentally, Pfizer, another multinational pharmaceutical giant, announced the acquisition of Biohaven for $11.
6 billion and GBT for $5.
4 billion on October 3 and 5
, respectively.
It is understood that Biohaven is a neurological disease drug development company, the main migraine drug Nurtec ODT net revenue in the first quarter of 2022 of $124 million, Pfizer's acquisition is mainly to win this drug
.
Upon completion of the acquisition, Biohaven's amyotrophic lateral sclerosis and obsessive-compulsive medical business will be spun off into the new Biohaven
.
The acquisition is one of the
world's largest pharmaceutical acquisitions in 2022.
GBT was founded in 2011 to develop therapeutic drugs
for sickle cell disease.
In 2019, GBT's sickle cell disease treatment Oxbryta was approved in the United States, and two more drugs are in the clinical stage
of phase 3-4.
The Pfizer acquisition will strengthen its business
in rare diseases.
In fact, in recent years, with policy support and market demand, major pharmaceutical companies are accelerating the layout of
rare diseases.
Earlier this year, GSK took the lead
.
In April 2022, GSK acquired Sierra
, a targeted therapy company for rare cancers, for $1.
9 billion.
Sierra Oncology focuses on the development of targeted therapies for rare tumors, and its main product candidate, momelotinib, has submitted a new drug application for the treatment of myelofibrosis to the US FDA in June this year, and is expected to be launched
in the United States in 2023.
At the same time, GSK expects to submit a new drug approval application
for the product in Europe in the second half of 2022.
In November 2021, Merck announced the completion of the acquisition of Acceleron Pharma, a new drug research and development company for rare diseases, for $11.
5 billion, it is reported that Acceleron is a clinical-stage biopharmaceutical company focusing on the research and development
of anti-cancer drugs and rare drugs for rare diseases.
In December 2021, Merck again acquired Chord Therapeutics, a drug research and development company focusing on rare neuroinflammatory diseases, with the help of this acquisition, Merck will obtain CRD1, a pipeline drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG), further strengthening the layout
of rare diseases.
In December 2021, Novartis announced the acquisition of neuroscience drug developer Cadent Therapeutics for up to $770 million
.
As part of the acquisition, Novartis acquired Cadent's rare disease products CAD-9303 and CAD-1883, of which CAD-9303 is used for schizophrenia and CAD-1883 is used for movement disorders such as cerebellar ataxia
.
Earlier, on January 8, 2019, Takeda Pharmaceutical spent $64 billion to acquire the American company Shire, becoming the number one giant
in rare diseases.
M&A Blue Ocean
M&A Blue Ocean Rare diseases, also known as "orphan diseases", refer to those diseases with a very low incidence, generally chronic, severe diseases, often endangering the lives of
patients.
According to the official website of the American Organization for Rare Diseases (NORD), there are currently more than 70,000 known rare diseases in the world, and the number of rare disease patients has exceeded 300 million, of which 50% of patients are children
.
Due to the small number of applicable people and high R&D costs, pharmaceutical companies rarely invest in R&D and production, so rare disease drugs are also called "orphan drugs"
.
Sullivan's "2022 China Rare Disease Industry Trend Observation Report" pointed out that in recent years, capital has continued to pour into the research and development of rare disease drugs, innovative biotechnology platforms, Internet technology and innovative medical services, which has promoted the construction of rare disease ecosystems, and various resources have been synergistic with each other, injecting vitality
into the rare disease industry chain.
into the rare disease industry chain.
Meng Lilian, chief expert of Sichuan Tianfu Health Industry Research Institute, pointed out in an interview with the "China Times" reporter that rare diseases seem to be a large population, but rare diseases are a general term for all rare diseases, and the number of people for each rare disease is not very large
.
People suffering from rare diseases need to receive effective drugs, which is their right and the obligation of the
state, enterprises and interested parties.
With the gradual availability of various conditions, the development of rare disease drugs has been paid attention to, and capital from all walks of life has gradually entered the field of rare diseases, which is the result of
common concern and expectation of all parties.
Deng Zhidong, general manager of Hainan Boao Medical Technology Co.
, Ltd.
, said in an interview with the "China Times" reporter that the total number of rare disease patients worldwide has exceeded 300 million, the number of rare disease patients in China is about 20 million, and the number of new patients exceeds 200,000 every year, and it is expected that by 2024, the global rare disease drug market will reach 242 billion US dollars
.
He further pointed out that in recent years, the research and development of rare disease drugs has become an important field of international new drug research and development, and the market for rare diseases can be expected
in the future with social attention and policy support.
